CCB02

CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1[1].

Product Specifications

CAS Number

2100864-57-9

Product Name Alternative

(-)-Pindolol; (S)-(-)-Pindolol; S-Pindolol,ONO1109,ONO1101 (hydrochloride)

UNSPSC

12352005

Target

Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CCB02.html

Purity

99.93

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

N#CC1=C(OC)N=CC2=CC3=CC=CC=C3N=C12

Molecular Formula

C14H9N3O

Molecular Weight

235.24

References & Citations

[1]Mariappan A, et al. Inhibition of CPAP-tubulin interaction prevents proliferation of centrosome-amplified cancer cells. EMBO J. 2019 Jan 15;38 (2) . pii: e99876.